Source: globenewswire.com
Immunomedics Inc. has received a Complete Response Letter from the U.S. Food and Drug Administration (US FDA) for the Biologics License Application seeking accelerated approval of sacituzumab govitecan. This new drug will help treat patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. Immunomedics is a pharmaceutical company focusing on the development of antibody-drug conjugates for the treatment of cancer.
